English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This editorial refers to “Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada Syndrome”1 by P. Bordachar et al. on page 879 and ”Prevalence and prognosis of subjects with Brigada type ECG pattern in a young and middle-aged Finnish population”1 by M.J. Junttila et al. on page 874Brugada Syndrome is a relatively new clinical electro cardiographic entity with inordinate risk of sudden death in the absence of structural heart disease. However, the Brugada type of ECG changes have been known for almost half a century and observed in many asymptomatic individuals.1 Recommendations for such individuals in the literature are rather conflicting. Although some authors use the term asymptomatic Brugada syndrome, the relationship between asymptomatic patients with typical ECG abnormalities and clinical cases of Brugada syndrome is not clear. Indeed, the Brugada pattern may also be provoked by right ventricular pathology, by drugs (e.g., Class I A, C anti-arrhythmic drugs, tri-cyclic antidepressants, overdose of psychotropic agents and analgesics that exhibit sodium channel blocking properties) and can be associated with electrolyte abnormalities (i.e., hyperkalaemia and hypercalcaemia).2 In Brugada syndrome, affected individuals can usually be detected by the typical ECG pattern, although not all patients have such an ECG and can only be diagnosed by drug challenges with IV ajmaline, flecainide or procainamide.In a recent review, a systematic literature search was performed in order to identify publications on the Brugada syndrome and the Brugada sign with special emphasis on analysing the outcome … *Correspondence to: Prof. Ali Otto, Department Cardiology, Hacettepe University School of Medicine, 06100 Ankara, Turkey. Tel.: +90-312-441-4262; fax: +90-312-441-4263  E-mail address: alioto{at}superonline.com

Brugada sign: a normal variant or a bad omen? Insights for risk stratification and prognostication